We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Trial of Growth Hormone in MPS I, II, and VI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00748969
Recruitment Status : Terminated (Insufficient recruitment.)
First Posted : September 9, 2008
Results First Posted : November 24, 2014
Last Update Posted : September 5, 2018
Information provided by (Responsible Party):
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Brief Summary:
The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.

Condition or disease Intervention/treatment Phase
Mucopolysaccharidosis I Mucopolysaccharidosis II Mucopolysaccharidosis VI Drug: Somatropin (DNA origin) Phase 2 Phase 3

Detailed Description:

Although children with MPS I, II, and VI who are treated with Hematopoietic Cell Transplantation (HCT) and/or enzyme replacement therapy (ERT) are living into adulthood with good cognitive development, their quality of life is significantly impacted by their skeletal abnormalities (i.e., kyphosis, scoliosis, and genu valgum), contractures, and severe short stature. Here at the University of Minnesota we have seen some promising clinical outcomes in children with MPS IH whom we have treated with human growth hormone (hGH). There are currently no reports in the literature of the impact of treating children with MPS and short stature, with hGH on their growth velocity or characteristic skeletal abnormalities. This study will advance the care of these children by providing data in this yet unexplored area of pediatric medicine with the goal of improving the quality of life for these children by improving height, mobility, and neuropsychological functioning.

This is a Phase II/III randomized, single-center, 12 month clinical trial of growth hormone in male and female participants with MPS I, II, or VI, followed by 12 months open label. Participants with height ≤ -2 SDS for age and gender will be randomized for the first 12 months 1:1 to treatment or no treatment. At the conclusion of the 12 months, all subjects will be offered an additional 12 months of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II/III, Randomized, Clinical Trial of the Effects of Nutropin AQ® on Growth and Bone Metabolism in Children With MPS I, II, and VI and Short Stature
Study Start Date : November 2008
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Arm Intervention/treatment
Experimental: Growth hormone treatmen
Growth hormone treatment arm. Somatropin (DNA origin)
Drug: Somatropin (DNA origin)
The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
Other Name: Nutropin AQ

No Intervention: No growth hormone treatment in year 1
No growth hormone treatment in year 1; option for treatment in year 2 open-label period.

Primary Outcome Measures :
  1. Change in Growth Velocity From Baseline to End of Study Year 1. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Safety: Number Drug Related SAEs [ Time Frame: 1 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A parent or legally authorized representative must provide written informed consent and comply with study assessments for the full duration of the study.
  • Chronologic age ≥ 5 years and bone age ≤12 years
  • Diagnosis of MPS I, II, or VI
  • Height ≤ -2 SDS for age and gender
  • Ability to travel to study center for evaluations.
  • Ability of the participant to cooperate with study procedures, to notify a guardian of symptoms, and provide assent for participation in the study.

Exclusion Criteria:

  • History of treatment with hGH
  • Untreated pituitary deficiency
  • Pregnancy (positive urine pregnancy test) prior to enrollment in the study
  • Participation in another simultaneous medical intervention trial
  • Patients with closed epiphysis
  • Active neoplasm
  • Orthopedic procedure of the femur within the last 6 months.
  • Known or suspected allergy to trial product or related products.
  • Structural lesion on brain MRI resulting in brain compression
  • Any other social or medical condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.
  • Obstructive sleep apnea without BiPAP or tonsillectomy/adenoidectomy treatment.
  • CNS shunt.
  • Abnormal cardiac function based on echocardiogram within 6 months prior to enrollment :
  • Ejection fraction less than 50%
  • Left ventricular chamber size greater than or less than 2 standard deviations of normal for body surface area
  • Left ventricular wall thickness greater than or less than 2 standard deviations of normal for body surface area
  • More than mild to moderate aortic insufficiency with abdominal aortic run-off
  • More than mild to moderate mitral insufficiency with pulmonary hypertension
  • Abnormal pulmonary function based on pulmonary function tests within 6 months prior to enrollment:
  • abnormal FVC < 80% of predicted for age, gender, and height
  • abnormal FEV1 < 80% predicted for age, gender, and height
  • abnormal FEV1/FVC
  • abnormal oxygen saturation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00748969

Layout table for location information
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Layout table for investigator information
Principal Investigator: Lynda E Polgreen, M.D. University of Minnesota
Layout table for additonal information
Responsible Party: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
ClinicalTrials.gov Identifier: NCT00748969    
Other Study ID Numbers: 0808M43681
First Posted: September 9, 2008    Key Record Dates
Results First Posted: November 24, 2014
Last Update Posted: September 5, 2018
Last Verified: November 2014
Keywords provided by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:
growth hormone
short stature
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucopolysaccharidosis II
Mucopolysaccharidosis I
Mucopolysaccharidosis VI
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Connective Tissue Diseases
Metabolic Diseases
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System